Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects

Song, Zhiwang; Lin, Yifei; Zhang, Xia; Feng, Chan; Lu, Yonglin; Gao, Yong; Dong, Chunyan

doi:10.2147/ijn.s125573

Cited by 86 publications

(50 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, apatinib-loaded liposomes were surface modified with targeting ligand, cyclic arginylglycylaspartic acid (cRGD), to specifically recognize αvβ3 integrin. 104 These cRGDanchored liposomes, compared with nontargeted liposomes, showed improved cellular uptake and inhibition of tumor growth in human colon HCT116 cancer cell line. Similarly, Wu et al 105 investigated the effect of folate targeting on the antitumor efficacy of paclitaxel-encapsulated PMs in human esophageal cancer cell lines, EC9706.…”

mentioning

confidence: 95%

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Din

Aman

Ullah³

et al. 2017

IJN

1,106

481

View full text Add to dashboard Cite

Nanotechnology has recently gained increased attention for its capability to effectively diagnose and treat various tumors. Nanocarriers have been used to circumvent the problems associated with conventional antitumor drug delivery systems, including their nonspecificity, severe side effects, burst release and damaging the normal cells. Nanocarriers improve the bioavailability and therapeutic efficiency of antitumor drugs, while providing preferential accumulation at the target site. A number of nanocarriers have been developed; however, only a few of them are clinically approved for the delivery of antitumor drugs for their intended actions at the targeted sites. The present review is divided into three main parts: first part presents introduction of various nanocarriers and their relevance in the delivery of anticancer drugs, second part encompasses targeting mechanisms and surface functionalization on nanocarriers and third part covers the description of selected tumors, including breast, lungs, colorectal and pancreatic tumors, and applications of relative nanocarriers in these tumors. This review increases the understanding of tumor treatment with the promising use of nanotechnology.

show abstract

mentioning

confidence: 95%

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Din

Aman

Ullah³

et al. 2017

IJN

1,106

481

View full text Add to dashboard Cite

show abstract

“…2,7 The insertion of ligand molecules having specificity to tumorspecific surface receptors or endothelial cells directly into neovascular vessels of a tumor is regarded as effective approach providing cancer cell specificity to nanocarriers. [8][9][10][11] To control drug release profiles, external stimuli-sensitive properties such as temperature, pH, magnetic field and light have been applied for nanocarriers. [12][13][14][15][16][17][18][19][20][21] ThermoDox is one example of a temperature-responsive liposome designed to achieve drug release at tumor tissues under local heating of tumor tissues.…”

Section: Introductionmentioning

confidence: 99%

Hyaluronic Acid-Based pH-Sensitive Polymer-Modified Liposomes for Cell-Specific Intracellular Drug Delivery Systems

Miyazaki

Yuba

Hayashi³

et al. 2017

Bioconjugate Chem.

View full text Add to dashboard Cite

For the enhancement of therapeutic effects and reduction of side effects derived from anticancer drugs in cancer chemotherapy, it is imperative to develop drug delivery systems with cancer-specificity and controlled release function inside cancer cells. pH-sensitive liposomes are useful as an intracellular drug delivery system because of their abilities to transfer their contents into the cell interior through fusion or destabilization of endosome, which has weakly acidic environment. We earlier reported liposomes modified with various types of pH-sensitive polymers based on synthetic polymers and biopolymers as vehicles for intracellular drug delivery systems. In this study, hyaluronic acid (HA)-based pH-sensitive polymers were designed as multifunctional polymers having not only pH-sensitivity but also targeting properties to cells expressing CD44, which is known as a cancer cell surface marker. Carboxyl group-introduced HA derivatives of two types, MGlu-HA and CHex-HA, which have a more hydrophobic side chain structure than that of MGlu-HA, were synthesized by reaction with various dicarboxylic anhydrides. These polymer-modified liposomes were stable at neutral pH, but showed content release under weakly acidic conditions. CHex-HA-modified liposomes delivered their contents into CD44-expressing cells more efficiently than HA-modified or MGlu-HA-modified liposomes or unmodified liposomes, whereas the same liposomes were taken up only slightly by cells expressing CD44 proteins less. Competition assay using free HA or other polymers revealed that HA derivative-modified liposomes might be recognized by CD44. Therefore, HA-derivative-modified liposomes are useful as cell-specific intracellular drug delivery systems.

show abstract

“…Enhancement of cellular uptake of drugs by actively-targeted nanoparticles is widely supported by the literature. Song et al [20] showed that cellular uptake of liposomal apatinib was enhanced by the conjugation of cyclic-RGD to the liposomal DD system. An 11.2-fold increase in cellular uptake was achieved by the modification of a liposomal doxorubicin system with an SP5-2 moiety by Chang et al [21] Transferrinmodified nanoparticles demonstrated a six-fold increase in uptake versus control liposomes for a breast cancer cell line [22].…”

Section: Structure Of Nanocarriersmentioning

confidence: 99%

Ultrasonically controlled estrone-modified liposomes for estrogen-positive breast cancer therapy

Salkho

Paul

Kawak

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

A new modality of drug targeting to tumors has been proposed. The ligand-mediated approach, that already increases the therapeutic index of the drug, can still be optimized by the encapsulation of the drug into sonosensitive nanoparticles. In this work, an endogenous ligand, estrone, was used to synthesize doxorubicin-encapsulating liposomes for estrogen receptor (ER)-positive breast cancer therapy with cyanuric chloride (2,4,6 trichloro-1,3,5 triazine) being used as a linking molecule to attach 3-OH group of estrone to the surface of liposomes. Then, drug release from liposomes was studied using ultrasound waves as a triggering mechanism with different frequencies and power densities. In addition, drug uptake by two cell lines ER-positive (MCF-7) and ER-negative (MDA-MB-231) was assessed, with the former cell line being examined later to study the synergetic effect of the receptor mediator targeting and ultrasound trigger. The sizes of the liposomes loaded with calcein (as a doxorubicin model drug) were determined by dynamic light scattering, and they were characterized as large unilamellar vesicles (LUVs). The release from the prepared liposomes triggered by ultrasound (US) waves at low frequency (20 kHz) and high frequency (1.07 and 3.24 MHz), at several power densities, was determined by monitoring the changes in calcein fluorescence, using a spectrofluorometer. Increasing power densities showed a significant effect on release at high frequencies and during the first two US pulses at low frequency. The echogenicity of the liposomes was proven and characterized at different power densities and frequencies. To confirm the viability of the carrier as a doxorubicin carrier, doxorubicin-encapsulating liposomes were prepared using the ammonium sulfate transmembrane gradient method. The liposomes were LUVs and were US-sensitive, exhibiting similar behavior to calcein-encapsulating liposomes. The calcein uptake by an ER + cell line (MCF-7) was compared with the uptake by an ER-cell line (MDA-MB-231). The MCF-7 uptake was significantly higher than the MDA-MB-231 uptake, which proved the targeting potential of estrone-conjugated liposomes. The exposure to low-frequency ultrasound (LFUS) revealed a statistically significant uptake of calcein compared to uptake without ultrasound. The described drug delivery (DD) system, comprising a new echogenic liposomal formulation, promises a non-immunogenic and site-specific biomedical approach to ER-positive breast cancer therapy.

show abstract

Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects

Cited by 86 publications

References 43 publications

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors

Hyaluronic Acid-Based pH-Sensitive Polymer-Modified Liposomes for Cell-Specific Intracellular Drug Delivery Systems

Ultrasonically controlled estrone-modified liposomes for estrogen-positive breast cancer therapy

Contact Info

Product

Resources

About